Articles

Patients can instantly save up to $200 off their copay with each prescription for PediatRx’s Granisol, the only FDA-approved ready-to-use liquid solution of granisetron. This new copay assistance program also leverages technology to initiate prior approval if a patient’s insurance requires it.

 

Women may be at greater risk for breast cancer if they start hormonal therapy before or soon after menopause, according to a large prospective study. Women who begin therapy 5 or more years after menopause are at less risk.

 

By training men with prostate cancer scheduled for prostatectomy on stress management techniques, nurses can help them raise their immune outcome and lower their mood disturbance. These outcomes, identified in a randomized study, build on the previous discovery that stress management techniques can improve quality of life 1 year postsurgery.

 

Avoiding intermittent high-dose dexamethasone (HD) when administering the vincristine/doxorubicin/dexamethasone (VAD) regimen can reduce the risk for bacterial infection in patients with multiple myeloma (MM), suggest the results of a Japanese study published in the January issue of the International Journal of Hematology.

 

 

Use of adjuvant chemotherapy may need to be rethought for patients who experience a pathologic complete response (pCR) or with ypT3-4 residual tumor after neoadjuvant chemoradiation (CRT) for rectal cancer, according to a new analysis presented at the 2011 Gastrointestinal Cancers Symposium (Abstract 361).

 

Although small, the US Food and Drug Administration (FDA) has identified an increased risk for developing anaplastic large cell lymphoma (ALCL) in the scar capsule adjacent to breast implants. Because the risk is small, nurses can help assure women that FDA-approved breast implants are safe when used correctly.

 

Everolimus plus octreotide LAR increases median progression-free survival over octreotide LAR alone in patients with advanced neuroendocrine tumors (NETs), according to the updated results of the RAD001 In Advanced Neuroendocrine Tumors (RADIANT-2) trial presented at the 2011 Gastrointestinal Cancers Symposium (Abstract 159).

 

Nimotuzumab shows the potential to improve both progression-free survival (PFS) and overall survival (OS) in patients with epidermal growth factor receptor (EGFR)-positive gastric cancer, according to results of a phase 2 randomized trial presented at the Gastrointestinal Cancers Symposium.